Jim Cramer is always looking near and far for ideas. He just found something big.» Read More
Apple dazzled investors with a big earnings beat, another big buyback and a dividend hike that should boost sentiment up and down Wall Street.
Biotech earnings kick off Tuesday after the bell as Gilead and Amgen report. Here's what to watch for.
About 150 S&P 500 companies are scheduled to release results this week, in an earnings season that has been mediocre.
Shares of Biogen Idec, Celgene, Gilead Sciences, and Lexicon Pharmaceuticals recovered from last week's selloff.
Some of Thursday's midday movers:
CNBC's Jim Cramer speaks with Robert Hugin, Celgene chairman & CEO, about America's need to build a stronger and more sustainable ecosystem of innovation to continue as the world leader in biomedical innovation.
Some of Wednesday's midday movers:
Despite the recent meltdown in biotech, there are still areas of opportunity within the sector, Citi's Yaron Werber says.
*E* Trade and Netflix weigh on S&P 500 and Nasdaq. NEW YORK, April 4- U.S. stocks fell sharply on Friday as momentum shares like Netflix and TripAdvisor sold off for a second straight session, putting the Nasdaq on track for its second-worst day of the year.
*E* Trade and Netflix weigh on S&P 500 and Nasdaq. NEW YORK, April 4- The Nasdaq tumbled more than 2 percent on Friday as momentum stocks like Netflix and TripAdvisor sold off for a second straight session.
*E* Trade and Netflix weigh on the S&P 500 and the Nasdaq. NEW YORK, April 4- The Nasdaq tumbled more than 2 percent on Friday, led by another selloff in momentum stocks like Netflix and TripAdvisor, as investors ignored relatively strong March jobs data. Biogen Idec Inc fell 3.6 percent to $291.
*Mylan up on report of Meda AB buy. *Boeing considers Mercury Systems acquisition. Biogen Idec Inc fell 4.3 percent to $288.98.
*Mylan up on report of Meda AB buy. *Boeing considers Mercury Systems acquisition. "Overall, people are taking this as a sign there isn't some sort of underlying weakness in the economy," said Kate Warne, investment strategist at Edward Jones in St. Louis.
Some of the names on the move ahead of the open.
April 3- Mylan Inc on Thursday sued Celgene Corp to stop the latter's effort to keep generic versions of two drugs that generate $4.5 billion of annual sales off the market.
Jim Cramer has noticed that many individual investors share a common fear.
Talk about a tempestuous affair. It looks like investors are again falling for stocks that they scorned just days ago.
After a rough patch last week where investors sold some of the market's hottest stocks, momentum names led a sharp rally in the Nasdaq on Tuesday.
The big issue for this quarter will be: will they economy pick up? The big debate for this quarter will be growth versus value.
There’s a vicious new trend underway in the market and Cramer says stocks of perfectly good companies could take a big hit.